Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

[1]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[2]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[3]  Baoshan Zhang,et al.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.

[4]  Bette Korber,et al.  Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes , 2014, Journal of Virology.

[5]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[6]  M. Nussenzweig,et al.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.

[7]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[8]  D. Ho,et al.  Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36 , 2014, Journal of acquired immune deficiency syndromes.

[9]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[10]  James C Paulson,et al.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.

[11]  Mohammed Shameem,et al.  Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications , 2014, mAbs.

[12]  A. Heck,et al.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry , 2014, Nature Protocols.

[13]  D. Ho,et al.  Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus , 2014, Science.

[14]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[15]  Gwo-Yu Chuang,et al.  Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.

[16]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[17]  D. Ho,et al.  Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1 , 2013, Proceedings of the National Academy of Sciences.

[18]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[19]  J. Baeten,et al.  Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going? , 2013, Journal of acquired immune deficiency syndromes.

[20]  I. Apostol,et al.  Monoclonal antibody disulfide reduction during manufacturing , 2013, mAbs.

[21]  Baoshan Zhang,et al.  Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains , 2013, Proceedings of the National Academy of Sciences.

[22]  D. Ho,et al.  Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope , 2013, Journal of acquired immune deficiency syndromes.

[23]  Michael S. Seaman,et al.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.

[24]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[25]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[26]  D. Baltimore,et al.  Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission , 2012, Retrovirology.

[27]  M. Nussenzweig,et al.  Enhanced HIV-1 neutralization by antibody heteroligation , 2012, Proceedings of the National Academy of Sciences.

[28]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[29]  A. Lim,et al.  Disulphide bond reduction of a therapeutic monoclonal antibody during cell culture manufacturing operations , 2011, BMC proceedings.

[30]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[31]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[32]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[33]  B. Berges,et al.  The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment , 2011, Retrovirology.

[34]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[35]  A. Tenorio.  The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy , 2011, Current HIV/AIDS reports.

[36]  C. Petropoulos,et al.  Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab , 2011, Journal of Virology.

[37]  M. Y. Lei,et al.  Dimeric 2G12 as a Potent Protection against HIV-1 , 2010, PLoS pathogens.

[38]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[39]  Andrew M Goetze,et al.  Assessing monoclonal antibody product quality attribute criticality through clinical studies , 2010, mAbs.

[40]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[41]  Theodore W Randolph,et al.  Buffer-dependent fragmentation of a humanized full-length monoclonal antibody. , 2010, Journal of pharmaceutical sciences.

[42]  D. Ho,et al.  Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients , 2010, Journal of Virology.

[43]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[44]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[45]  D. Kuritzkes,et al.  Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults , 2008, Antimicrobial Agents and Chemotherapy.

[46]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[47]  Kevin R. Harwell.  United States Patent and Trademark Office , 2002 .

[48]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[49]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[50]  E. Padlan,et al.  A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. , 1997, AIDS research and human retroviruses.

[51]  J. J. Rosa,et al.  Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. , 1992, Journal of immunology.

[52]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[53]  Michael W. Laird,et al.  Thioredoxin 1 is responsible for antibody disulfide reduction in CHO cell culture. , 2012, Journal of biotechnology.

[54]  L. Jermutus,et al.  Aggregation, stability, and formulation of human antibody therapeutics. , 2011, Advances in protein chemistry and structural biology.